Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So you just assume it's proven
The share prices back up my opinions.
when company he's running has zero REVENUE.
1. It is not a scientific paper.
2. Xanthohumol starts showing significant antimicrobial and antifungal effects at around the 60mg range. Most beers contain .96mg xanthohumol per liter. A toss up between fighting off the coronavirus or dying of alcohol poisoning.
Science is your friend.
Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn explains: “Leronlimab inhibits migration of Tregs, which can inhibit the innate immune response against pathogens, into areas of inflammation. Most importantly, the migration of macrophages and the release of inflammatory cytokines including TNF and IL-6 (cytokine storm) is what causes the profound damage in the lungs in some patients. Leronlimab binding to CCR5 changes the macrophages migration and cytokine production. Taken together, these activities may reduce the morbidity and mortality in moderate to severe cases of COVID-19. IncellDx has developed a suite of diagnostics to monitor these effects of leronlimab on the immune system in these critical patients.”
According to your past technicals we should be sitting at .30. Your predictive abilities are woeful.
I agree with you Karen is in it to win it $$$$$$$$$$$$
If you think this is the bottom, just wait to see how many people can afford to buy shoes like these when they don't have a job and can't go anywhere.
In fact the smart investor will hold onto the right stocks and buy when it appears the bottom is in.
The drugs they propose for a cure that have been used for SARS and MERS have shown to have moderate efficacy at best. A vaccine will take quite a while to be shown as effective, no vaccine is 100% effective and is of use only with those who have actually taken the vaccine.
When leronlimab is proven as a treatment for COVID-19 the same MOA will be applicable to SARS, MERS, influenza and any other new virus who's vector includes respiratory failure.
Edward just drinks that because he thinks it's quite refreshing.
I have, which is why I chose to speculate on this company.
However, there is a difference between what you see in a lab and what is a marketable drug.
looks like big pharma has coronavirus handled No Play here
However, the only evidence of potential beyond HIV is sparse at best and the majority relies on what has come out of the press releases
viewmont, your post #33849 is your most intelligent post ever.
90%+ of the patients get ok without any medicine in 14 days - so why anyone will want to pay for medicine that needs treatment for 6 weeks.
Another little medical lesson for you. An infection usually lasts for a certain length of time until the body's own immune system overcomes it. If the virus overwhelms the immune system then it lasts longer and may lead to death.
I think your record of misinformation vastly exceeds NP's.
2020
Most other cv announcements were met with high SP increases and there was coverage - take INO, NVAX
NP just talks about how Lero will be effective on diverse diseases like HIV- 22 Cancers - GVHD - NASH and now CV.
Well just reading the lists above seems too good to true
Any deal with the U.S. government.
There are three options - No. 1 we set up subsidiaries and infrastructure in the EU and every other country in the world. No. 2 We don't allow any distribution outside the U.S. and let people die all over the world. No. 3 We out-license to other established companies throughout the world. No. 3 is the well established pattern for all biopharma, nothing at all strange about it.
Why is the US-administration not protecting what they have in the USA ?
Please misiu and ohm and all please question your DD again and again and again !
One of dozens of companies working on a vaccine. So there's a 1:40 or 1:50 chance of a particular company coming out on top. Look at what happened to the CEO who talked to Trump. Doesn't seem like any deal with CureVac is in the works.
https://www.fiercebiotech.com/biotech/was-it-something-he-said-biotech-ceo-who-met-president-trump-month-exits-without-a-word
The measurement for patient 3 was for CAMLs and there's a high degree of correlation between CAMLs, disease progression and survival.
https://www.ncbi.nlm.nih.gov/pubmed/28687903
You really should take some time out of your day to see how to properly evaluate pre-revenue biopharma.
Somehow an amazing drug unlike any other with billions to be made and you whine about irrelevant BS.
Hour after hour. 24 hours a day. 7 days a week. Day after day. Week after week. For weeks on end. Working over time is how it appears to me
Let’s not forget it could also mean they went dark to save themselves from suspension while they get caught up on the filings
What does this all mean?
There have been no credible scientific studies of this. It's about as likely as Filipino "doctors" pulling cancer out of your body just using their hands.
This made me laugh. Dump the rest and I'll be laughing all day,
We know you prefer no news and a share price crashing down to the trips. No wonder Cytodyn confuses you.
On October 2, Savara announced a response from a Type C meeting with the FDA over the drug. The agency indicated the data provided did not provide sufficient evidence of efficacy and safety and as a result, didn’t recommend Savara submit a Biologics License Application (BLA).
Unexpectedly, the Breakthrough Therapy designation was based on data from IMPALA.
I'll discount any opinion coming from someone who thinks coconut oil is a good HIV treatment.
we have, all have zero side effects allegedly.
With that being the case, why in the hell is the FDA ALWAYS asking for more information and delaying decisions?
For years, the only narrative we get is from Nader.
I’d prefer not to get the “Ohm spin” and responding with another question.
You seem to be skipping over one important word.
The review division will make a recommendation as to whether a request for a BTD is appropriate, may be too preliminary, or does not currently meet the criteria for a BTD.
And who knows?... Lets see if it happens.
Will COVID 19 help or be a detriment to CYDY?